IP Library Granted Patent US 12691075
Granted Patent B2
US 12691075 · App. 18/012,386 · Granted Jul 28, 2026

Enteric coating composition and method of making and using the same

Inventors: Steven Luedecke (St. Louis, MO); Houston Smith (St. Louis, MO)
Assignee: Sensient Colors LLC
A61K9/4891A23L29/10A23L29/231A23L29/256A23L29/30A23L29/37A23P20/105A61K9/4825A61K47/10A61K47/36A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691075
App. No.
18/012,386
Granted
Jul 28, 2026
Kind
B2
Abstract

A dosage form coating composition is disclosed. The composition includes an alginate, a pectin, a plasticizer, and optionally an emulsifying agent. The alginate is present in an amount by weight of at least 40.0% and at most 80.0% and the pectin is present in an amount by weight of at least 16.0% and at most 40.0%—and/or—the alginate and the pectin are present in a weight ratio of at least 1:1 and at most 5:1. The dosage form coating composition, when applied to a dosage form to a 3% to 5% weight gain, provides a coated dosage form having an enteric coating. The coated dosage form has at least two sequentially observed properties exhibiting enteric coating behavior.

Claims (32)

1 . A dosage form coating composition comprising:

an alginate in an amount by weight of at least 40.0% and at most 80.0%;

a pectin in an amount by weight of at least 16.0% and at most 40.0%; and

a plasticizer in an amount by weight of at least 0.5% and at most 30.0%;

wherein the dosage form coating composition, when applied to a dosage form to a 3% to 5% weight gain, provides a coated dosage form having an enteric coating and at least the following two sequentially observed properties:

(i) the enteric coating does not exhibit visible signs of dissolution after being immersed in a 0.1 M solution of hydrochloric acid or simulated gastric fluid at a predetermined temperature and for a first predetermined length of time, wherein the predetermined temperature is between 30° C. and 45° C., wherein the first predetermined length of time is between 15 minutes and 3 hours; and

(ii) after the being immersed in the 0.1 M solution of hydrochloric acid or simulated gastric fluid, the enteric coating is at least partially dissolved after being immersed in a phosphate buffer having a pH between 6.5 and 7.0 or simulated intestinal fluid at the predetermined temperature for a second predetermined length of time, wherein the second predetermined length of time is between 60 minutes and 6 hours.

2 . The dosage form coating composition of claim 1 , wherein the alginate and the pectin are present in a weight ratio of between 1:1 and 5:1.

3 . The dosage form coating composition of claim 1 , the dosage form coating composition comprising an emulsifying agent.

4 . The dosage form coating composition of claim 3 , wherein the emulsifying agent is a lecithin.

5 . The dosage form coating composition of claim 4 , wherein the lecithin is a sunflower lecithin.

6 . The dosage form coating composition of claim 3 , wherein the emulsifying agent is present in an amount by weight of between 0.1% and 10.0%.

7 . The dosage form coating composition of claim 1 , wherein the alginate is present in an amount by weight of between 45.0% and 80%.

8 . The dosage form coating composition of claim 1 , wherein the alginate is sodium alginate.

9 . The dosage form coating composition of claim 1 , wherein the alginate has a viscosity as measured at 10% solids of between 1 cP and 500 cP.

10 . The dosage form coating composition of claim 1 , wherein the pectin is present in an amount by weight of between 17.0% and 40.0%.

11 . The dosage form coating composition of claim 1 , wherein the pectin has a degree of esterification of between 40% and 55%.

12 . The dosage form coating composition of claim 1 , wherein the pectin is non-amidated.

13 . The dosage form coating composition of claim 1 , wherein the plasticizer is present in an amount by weight of between 2.5% and 30.0%.

14 . The dosage form coating composition of claim 1 , wherein the plasticizer is at least one of glycerine or coconut oil.

15 . The dosage form coating composition of claim 1 , wherein the predetermined temperature is between 35° C. and 39° C.

16 . The dosage form coating composition of claim 1 , the dosage form coating composition further comprising at least one of an opacifying agent, a sweetening agent, a flavor masking agent, a colorant, a spray dried flavorant, a dried crystal flavorant, a liquid flavorant, a granule flavorant, a spray dried sensate, a dried crystal sensate, a granule sensate, or a liquid sensate.

17 . The dosage form coating composition of claim 1 , wherein the composition is substantially free of cellulosic film formers.

18 . The dosage form coating composition of claim 1 , wherein the composition is substantially free of shellac.

19 . The dosage form coating composition of claim 1 , wherein the composition is substantially free of modified food starch.

20 . A dosage form coating composition comprising:

an alginate in an amount by weight of at least 40.0% and at most 80.0%;

a pectin; and

a plasticizer;

wherein the alginate and the pectin are present in a weight ratio of at least 1:1 and at most 5:1, wherein the dosage form coating composition, when applied to a dosage form to a 3% to 5% weight gain, provides a coated dosage form having an enteric coating and at least the following two sequentially observed properties:

(i) the enteric coating does not exhibit visible signs of dissolution after being immersed in a 0.1 M solution of hydrochloric acid or simulated gastric fluid at a predetermined temperature and for a first predetermined length of time, wherein the predetermined temperature is between 30° C. and 45° C., wherein the first predetermined length of time is between 15 minutes and 3 hours; and

(ii) after the being immersed in the 0.1 M solution of hydrochloric acid or simulated gastric fluid, the enteric coating is at least partially dissolved after being immersed in a phosphate buffer having a pH between 6.5 and 7.0 or simulated intestinal fluid at the predetermined temperature for a second predetermined length of time, wherein the second predetermined length of time is between 60 minutes and 6 hours.